These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26731611)

  • 1. 4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1).
    Hügle M; Lucas X; Weitzel G; Ostrovskyi D; Breit B; Gerhardt S; Einsle O; Günther S; Wohlwend D
    J Med Chem; 2016 Feb; 59(4):1518-30. PubMed ID: 26731611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
    Raj U; Kumar H; Varadwaj PK
    J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
    Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
    J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
    Tumdam R; Kumar A; Subbarao N; Balaji BS
    SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico design and bioevaluation of selective benzotriazepine BRD4 inhibitors with potent antiosteoclastogenic activity.
    Deepak V; Wang B; Koot D; Kasonga A; Stander XX; Coetzee M; Stander A
    Chem Biol Drug Des; 2017 Jul; 90(1):97-111. PubMed ID: 28032455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
    Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.
    Li J; Wang P; Zhou B; Shi J; Liu J; Li X; Fan L; Zheng Y; Ouyang L
    Eur J Med Chem; 2016 Oct; 121():294-299. PubMed ID: 27266999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.
    Duffy BC; Liu S; Martin GS; Wang R; Hsia MM; Zhao H; Guo C; Ellis M; Quinn JF; Kharenko OA; Norek K; Gesner EM; Young PR; McLure KG; Wagner GS; Lakshminarasimhan D; White A; Suto RK; Hansen HC; Kitchen DB
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2818-23. PubMed ID: 26022843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
    Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
    ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Acyl Pyrroles as Dual BET-BRD7/9 Bromodomain Inhibitors Address BETi Insensitive Human Cancer Cell Lines.
    Hügle M; Regenass P; Warstat R; Hau M; Schmidtkunz K; Lucas X; Wohlwend D; Einsle O; Jung M; Breit B; Günther S
    J Med Chem; 2020 Dec; 63(24):15603-15620. PubMed ID: 33275431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
    Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
    J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylpyrrole inhibitors of BET bromodomains.
    Hasvold LA; Sheppard GS; Wang L; Fidanze SD; Liu D; Pratt JK; Mantei RA; Wada CK; Hubbard R; Shen Y; Lin X; Huang X; Warder SE; Wilcox D; Li L; Buchanan FG; Smithee L; Albert DH; Magoc TJ; Park CH; Petros AM; Panchal SC; Sun C; Kovar P; Soni NB; Elmore SW; Kati WM; McDaniel KF
    Bioorg Med Chem Lett; 2017 May; 27(10):2225-2233. PubMed ID: 28268136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
    Hewings DS; Fedorov O; Filippakopoulos P; Martin S; Picaud S; Tumber A; Wells C; Olcina MM; Freeman K; Gill A; Ritchie AJ; Sheppard DW; Russell AJ; Hammond EM; Knapp S; Brennan PE; Conway SJ
    J Med Chem; 2013 Apr; 56(8):3217-27. PubMed ID: 23517011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
    Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS
    ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.
    Raux B; Voitovich Y; Derviaux C; Lugari A; Rebuffet E; Milhas S; Priet S; Roux T; Trinquet E; Guillemot JC; Knapp S; Brunel JM; Fedorov AY; Collette Y; Roche P; Betzi S; Combes S; Morelli X
    J Med Chem; 2016 Feb; 59(4):1634-41. PubMed ID: 26735842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
    Li X; Zhang J; Zhao L; Yang Y; Zhang H; Zhou J
    ChemMedChem; 2018 Jul; 13(13):1363-1368. PubMed ID: 29808961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET bromodomain inhibitors: a patent review.
    Garnier JM; Sharp PP; Burns CJ
    Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based virtual screening of novel, high-affinity BRD4 inhibitors.
    Muvva C; Singam ER; Raman SS; Subramanian V
    Mol Biosyst; 2014 Jul; 10(9):2384-97. PubMed ID: 24976024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.